Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical ...

Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer ...

Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm ...

The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...

Artificial intelligence (AI) is now infiltrating core industries and according to Forbes, the market is expected to reach a ...

In today's regulatory landscape, ensuring data integrity is crucial for compliance and process visibility. How can ...

SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its ...

The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is ...

Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of ...

The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.